Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients

References

• Diasio RB. Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology (Williston Park). 1999;13(Suppl):17–21.10442353
   PubMed Web of Science ®Google Scholar
• Namikawa T, Maeda H, Kitagawa H, et al. Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol. BMC Cancer. 2018;18(1):186. doi:10.1186/s12885-018-4242-829439671
   PubMed Web of Science ®Google Scholar
• Chhetri P, Giri A, Shakya S, Shakya S, Sapkota B, Pramod KC. Current development of anti-cancer drug S-1. J Clin Diagn Res. 2016;10(11):XE01–XE05. doi:10.7860/JCDR/2016/19345.8776
   PubMedGoogle Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–1820. doi:10.1056/NEJMoa07225217978289
   PubMed Web of Science ®Google Scholar
• Yoon DH, Kim SB. S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer? Expert Rev Anticancer Ther. 2010;10(5):659–662. doi:10.1586/era.10.4520469998
   PubMed Web of Science ®Google Scholar
• Fujii T, Horiguchi J, Yanagita Y, et al. Phase II study of S-1 plus trastuzumab for HER2-positive metastatic breast cancer (GBCCSG-01). Anticancer Res. 2018;38(2):905–909. doi:10.21873/anticanres.1230129374719
   PubMed Web of Science ®Google Scholar
• Li J, Xu R, Xu J, et al. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: regimen of 1 week on, 1 week off. Cancer Sci. 2017;108(10):2045–2051. doi:10.1111/cas.1333528763145
   PubMed Web of Science ®Google Scholar
• Zhu X, Ju X, Cao F, et al. Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial. BMC Open. 2016;6(12):e013220. doi:10.1136/bmjopen-2016-013220
   PubMed Web of Science ®Google Scholar
• Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–4393. doi:10.1200/JCO.2011.36.590822010012
   PubMed Web of Science ®Google Scholar
• Jeong JH, Park SR, Ahn Y, et al. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer. Gastric Cancer. 2017;20(1):146–155. doi:10.1007/s10120-015-0586-926715117
   PubMed Web of Science ®Google Scholar
• Tanner JA, Tyndale RF. Variation in CYP2A6 activity and personalized medicine. J Pers Med. 2017;7(4):E18. doi:10.3390/jpm704001829194389
   PubMed Web of Science ®Google Scholar
• Kim MJ, Kong SY, Nam BH, Kim S, Park YI, Park SR. A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clnical and pharmacogenetics results. Pharmacogenet Genomics. 2018;28(1):23–30. doi:10.1097/FPC.000000000000032029189588
   PubMed Web of Science ®Google Scholar
• Meulendijks D, Henricks LM, van Kuilenburg AB, et al. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines. Cancer Chemother Pharmacol. 2016;78(4):875–880. doi:10.1007/s00280-016-3137-027544765
   PubMed Web of Science ®Google Scholar
• Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018;103(2):210–216. doi:10.1002/cpt.91129152729
   PubMed Web of Science ®Google Scholar
• Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer. 2004;91(10):1769–1774. doi:10.1038/sj.bjc.660220815505626
   PubMed Web of Science ®Google Scholar
• Hirata K, Horikoshi N, Aiba K, et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res. 1999;5(8):2000–2005.10473078
   PubMed Web of Science ®Google Scholar
• Chu QS, Hammond LA, Schwartz G, et al. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res. 2004;10(15):4913–4921. doi:10.1158/1078-0432.CCR-04-046915297391
   PubMed Web of Science ®Google Scholar
• Furuse J, Okusaka T, Kaneko S, et al. Phase I/II study of the pharmacokinetics, safety, and efficacy of S-1 in patients with advanced hepatocellular carcinoma. Cancer Sci. 2010;101(12):2606–2611. doi:10.1111/j.1349-7006.2010.01730.x20946314
   PubMed Web of Science ®Google Scholar
• Shirasaka T, Shimamoto Y, Fukushima M. Inhibition of oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993;53(17):4004–4009.7689420
   PubMed Web of Science ®Google Scholar
• Liu K, Zhong D, Zou H, Chen X. Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2010;52(4):550–556. doi:10.1016/j.jpba.2010.01.02620138454
   PubMed Web of Science ®Google Scholar
• Korea Ministry of Food and Drug Safety (MFDS). [Guideline on Bioequivalence Studies for Orally Administered Drug Products (No. 2017-28)]. Korean Available from: https://www.mfds.go.kr/brd/m_211/view.do?seq=11835. Accessed 220, 2019.
   Google Scholar
• TS-ONE®. Capsule 20 [package Insert]. Tokyo, Japan: Taiho Pharmaceutical Co. Ltd.; 2017.
   Google Scholar